Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Prevention of inhibitor development in hemophilia A in 2016. A glimpse into the future?

Thrombosis research - 1 Dec 2016

Franchini Massimo, Lippi Giuseppe

Abstract excerpt

Thanks to considerable progresses made over the last 30years, hemophilia benefits from the most efficacious and safe treatment among the many monogenic inherited disorders. The most challenging complication of replacement therapy in hemophilia A is the occurrence of alloantibodies against infused factor VIII (FVIII), thus predisposing the patients to increased morbidity and disability. Extensive research in this...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Mutation
Share to Factor VIII
Share to Hemophilia A

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Isoantibodies

Share to Recombinant Proteins

Source

Identifiers

PMID: 27816852
DOI: 10.1016/j.thromres.2016.10.024

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Prevention of inhibitor development in hemophilia A in 2016. A glimpse into the future?PMID 27816852Read ↗

A close insight to factor VIII inhibitor in the congenital hemophilia A.Semantic proximity Read ↗

Development of inhibitors in hemophilia A: An illustrated reviewSemantic proximity Read ↗

Assessing risk factors: prevention of inhibitors in haemophilia.Semantic proximity Read ↗

Acquired hemophilia A: Updated review of evidence and treatment guidance.Semantic proximity Read ↗

Haemophilia.Semantic proximity Read ↗

The Evolution of Hemophilia Care: Clinical and Laboratory Advances, Opportunities, and ChallengesSemantic proximity Read ↗

[Research Progress on Genetic Factors and Hemophilia A Clotting Factor Inhibitor-Review].Semantic proximity Read ↗

Inhibitor development in hemophiliacs: the roles of genetic versus environmental factors.Semantic proximity Read ↗

Why do inhibitors develop? Principles of and factors influencing the risk for inhibitor development in haemophilia.Semantic proximity Read ↗

Key insights to understand the immunogenicity of FVIII products.Semantic proximity Read ↗

Hemophilia A and B: molecular and clinical similarities and differencesSemantic proximity Read ↗

The incidence and treatment of bleeding episodes in non-severe haemophilia A patients with inhibitors.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.